Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Lutathera
Related studies linked through entity extraction aliases.
Biomarker Identification of Radionuclide Therapy-induced Radiation Responses
- Status
- UNKNOWN
- Phase
- NA
Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
- Status
- RECRUITING
- Phase
- PHASE1
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
- Status
- UNKNOWN
- Phase
- PHASE2
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Post-Authorization Long-Term Safety Study of LUTATHERA
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A